Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Dacomitinib versus gefitinib as first-line treatment for ... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
0
Authors
Yi‐Long Wu
20 more
Yi‐Long Wu
•
R. Linke
18 more
•
Tony Mok
Published
September 25, 2017
Paper
Conversation
0
Reviews
0
Bounties
0
Abstract
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
The Lancet Oncology
Topics
Medicine
Cancer Oncology
Internal Medicine
Pulmonary And Respiratory Medicine
Cancer
Show all topics
DOI
10.1016/s1470-2045(17)30608-3
